Hartford Funds Management Co LLC Has $3.46 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Hartford Funds Management increased its Eli Lilly stake by 74.6% in the fourth quarter, buying 1,373 more shares and bringing its position to 3,214 shares worth about $3.46 million.
• Institutional ownership in Eli Lilly remains very high, with 82.53% of the stock held by hedge funds and other institutions. Several other funds also recently added to or initiated positions in LLY.
• Analysts remain broadly bullish on Eli Lilly, with an average Moderate Buy rating and a consensus price target of $1,218.33. The company also reported strong quarterly results, beating EPS and revenue estimates, while issuing FY2026 EPS guidance of 35.5 to 37.0.

Hartford Funds Management Co LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 74.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,214 shares of the company's stock after buying an additional 1,373 shares during the quarter. Eli Lilly and Company makes up approximately 0.3% of Hartford Funds Management Co LLC's portfolio, making the stock its 17th largest position. Hartford Funds Management Co LLC's holdings in Eli Lilly and Company were worth $3,456,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares during the period. 10Elms LLP boosted its holdings in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after buying an additional 24 shares during the period. Finally, Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $33,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on LLY. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an "overweight" rating in a report on Friday, May 1st. Morgan Stanley restated an "overweight" rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a report on Friday, May 1st. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Finally, Wolfe Research restated an "outperform" rating and set a $1,325.00 price target on shares of Eli Lilly and Company in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,218.33.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Eli Lilly and Company Stock Performance

LLY stock opened at $988.76 on Tuesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market cap of $931.15 billion, a P/E ratio of 35.12, a P/E/G ratio of 1.09 and a beta of 0.48. The firm has a 50 day simple moving average of $940.00 and a 200 day simple moving average of $999.39. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.